S&P 500 Financials Sector SEC Filings — March 12, 2026

12-03-2026

NewMarket Corporation (NEU) has filed Definitive Additional Proxy Materials (DEFA14A) for its Annual Meeting of Shareholders on April 23, 2026, at 10:00 A.M. EDT at The Foundry Building in Richmond, VA. Shareholders will vote on electing seven director nominees recommended by the Board, ratifying PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026, and providing advisory approval of named executive officer compensation. Proxy materials are available online at www.envisionreports.com/NEU, with paper copy requests due by April 13, 2026, and electronic votes required by 1:00 A.M. EDT on April 23, 2026.

• ·Proxy materials request deadline: April 13, 2026
• ·Electronic voting deadline: 1:00 A.M. EDT on April 23, 2026
• ·Meeting location: The Foundry Building, 500 Tredegar St., Richmond, VA 23219

12-03-2026

Avery Dennison Corporation (AVY) issued definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on April 30, 2026, held virtually. Shareholders will vote on electing 10 director nominees (all Board-recommended FOR), advisory approval of executive compensation (FOR), ratification of PwC as independent auditor for fiscal year 2026 (FOR), and a stockholder proposal for an independent Board Chairman (Board recommends AGAINST). Voting must be completed by April 29, 2026 11:59 PM ET (April 27 for plan shares).

• ·Proxy materials available online at www.ProxyVote.com or request paper/email copy by April 16, 2026
• ·Virtual meeting access at www.virtualshareholdermeeting.com/AVY2026 starting 12:00 P.M. ET
• ·Filing date: March 12, 2026

12-03-2026

Citizens Financial Services, Inc. filed its 2026 Proxy Statement on March 12, 2026, for the annual meeting on April 21, 2026, recommending ratification of S.R. Snodgrass, P.C. as independent auditor for the fiscal year ending December 31, 2026. Total fees for audit and related services declined 14% YoY to $350,679 in 2025 from $408,720 in 2024; however, audit fees increased 1.7% to $316,247 while other fees dropped sharply 80% to $15,840. Directors and executive officers as a group beneficially own 5.5% of common stock (266,092 shares) as of March 2, 2026, with Roger C. Graham, Jr. holding 1.4%.

• ·Several insiders have pledged shares as collateral: Thomas E. Freeman (4,000 of 12,972 shares), Roger C. Graham, Jr. (5,015 of 68,679 shares), Stephen J. Guillaume (1,280 of 4,656 shares), Terry B. Osborne (3,477 of 13,173 shares), John P. Painter II (800 of 2,738 shares).

12-03-2026

ProFrac Holding Corp. reported full year 2025 revenue of $1.94B, down 11% YoY from $2.19B, with Adjusted EBITDA declining 38% to $310M (16% margin vs 23% prior) and net loss widening to $356M from $208M. However, Q4 2025 showed sequential QoQ gains, with revenue up 8% to $437M from $403M and Adjusted EBITDA surging 49% to $61M from $41M. The company anticipates softer Q1 2026 due to weather disruptions impacting Adjusted EBITDA by $8M-$12M but targets $100M annualized savings by end-Q2 2026 and 2026 capex of $155M-$185M.

• ·Stimulation Services: FY2025 revenue $1.68B, Adjusted EBITDA $209M (12.4% margin); Q4 revenue $384M, Adjusted EBITDA $33M (8.6% margin)
• ·Proppant Production: FY2025 revenue $336M, Adjusted EBITDA $57M (17.0% margin); Q4 revenue $115M, Adjusted EBITDA $16M (13.9% margin)
• ·Manufacturing: FY2025 revenue $212M (wait, $212M), Adjusted EBITDA $19M (9.0% margin); Q4 revenue $43M, Adjusted EBITDA $4M (9.3% margin)
• ·Flotek: FY2025 revenue $244M, Adjusted EBITDA $38M (15.6% margin); Q4 revenue $70M, Adjusted EBITDA $10M (14.3% margin)
• ·Other Business Activities: FY2025 revenue $17.3M, Adjusted EBITDA -$0.2M (-1.2% margin)
• ·Total principal debt $1.05B as of Dec 31, 2025; cash $23M (of which $6M Flotek-related)
• ·2026 capex guidance $155M-$185M (ex-Flotek: $145M-$175M)

12-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 12, 2026, announcing the issuance of a press release titled 'AITX's RAD Announces New Orders Reflecting Ongoing Market Demand,' attached as Exhibit 99.1. The filing indicates positive ongoing market demand for RAD products but provides no specific details on order volumes, values, or comparisons to prior periods.

• ·Filing includes Item 8.01 (Other Events) and Item 9.01 (Exhibits).
• ·Information is furnished, not filed, and not deemed material.

12-03-2026

Southwest Airlines Co. entered into a $500M senior secured term loan credit facility with BNP Paribas on March 11, 2026, which was fully drawn on closing and matures on March 11, 2029. The facility allows prepayments without penalty and includes an uncommitted incremental feature for up to an additional $500M. It is secured by certain aircraft and related assets, with interest at Term SOFR + 1.10% (floor 0.00%) or Alternate Base Rate + 0.10% (floor 1.00%).

• ·Amounts prepaid under the facility may not be reborrowed.
• ·The facility includes customary covenants, representations, warranties, and events of default, with a minimum collateral coverage ratio requirement.
• ·The full Term Loan Credit Agreement will be filed in the Quarterly Report for the fiscal quarter ending March 31, 2026.

12-03-2026

Upexi, Inc. (UPXI) filed an 8-K on March 12, 2026, furnishing an investor presentation (Exhibit 99.1) under Item 7.01 Regulation FD Disclosure, to be used in meetings with investors and analysts on or after March 11, 2026. The presentation provides an overview of the company's business, strategy, operations, Solana treasury strategy, and capital markets activities. No specific financial metrics, performance data, or period-over-period comparisons are disclosed in the filing.

• ·Filing intended to satisfy Regulation FD obligations.
• ·Presentation information is furnished, not filed, and not subject to Section 18 liabilities.
• ·Company is an emerging growth company.

12-03-2026

EPAM Systems, Inc. announced its Investor Day on March 12, 2026, starting at 8:30 a.m. ET, featuring presentations by CEO and President Balazs Fejes, CFO Jason Peterson, and other leadership team members. Selected slides from the presentations are furnished as Exhibit 99.1 and webcast live with replay available on the investor relations website at https://investors.epam.com.

• ·Information in Item 7.01 and Exhibit 99.1 not deemed 'filed' under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.

12-03-2026

Ribbon Acquisition Corp., a blank check company, announced the adjournment of its Extraordinary General Meeting originally scheduled for March 12, 2026 at 10:00 a.m. ET, to allow additional time to solicit proxies for the proposals outlined in the proxy statement. The Company will announce the new date and time once determined, with shareholders of record as of February 18, 2026 entitled to vote and prior proxies remaining valid unless revoked.

• ·Meeting adjourned on March 11, 2026 (filing as of date)
• ·Securities traded on The Nasdaq Stock Market LLC
• ·Company address: Central Park Tower LaTour Shinjuku, Room 3001, 6-15-1 Nishi Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
• ·Emerging growth company: yes

12-03-2026

Ibotta, Inc. announced on March 11, 2026, that its Board of Directors approved an increase to the existing Share Repurchase Program by an additional $100 million, following the original $300 million authorization approved in August 2024. The program, now with up to $400 million total capacity, has no expiration date and permits repurchases through open market transactions or private negotiations, subject to market conditions and legal requirements.

• ·Repurchases may be conducted in accordance with Rule 10b-18 or via Rule 10b5-1 plans.
• ·The company is not obligated to repurchase any specific amount and may terminate or suspend the program at any time.
• ·Class A Common Stock trades on the New York Stock Exchange under symbol IBTA.

12-03-2026

LQR House Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on March 11, 2026, enabling the company to offer and sell up to $50.3M of common stock through an at-the-market (ATM) offering pursuant to its Form F-3 Registration Statement (File No. 333-282118). Proceeds are expected to fund capital expenditures, potential acquisitions, sales and marketing, working capital, and general corporate purposes. The Sales Agent will receive a 3.0% commission on gross proceeds, with no obligation for the company to sell any shares.

• ·Agreement dated March 11, 2026; filed March 12, 2026
• ·Sales pursuant to Registration Statement on Form F-3 (File No. 333-282118) and prospectus supplement dated March 11, 2026
• ·Sales Agreement attached as Exhibit 10.1

12-03-2026

Stoneridge reported FY2025 sales of $861.3M and adjusted EBITDA of $25.0M (2.9% margin), outperforming end-markets by 150 bps driven by MirrorEye growth of 69% to $111M, material cost improvements of 80 bps, and $6.6M reduction in quality costs. However, Electronics sales declined 7.3% YoY to $551.4M, Control Devices sales fell 6.2% to $277.9M, and the company posted a net loss of $102.8M due to $21.6M asset impairment and $44.5M tax valuation allowances. Guidance includes 2026 revenue of $625-650M (4.2% growth ex-Control Devices) and EBITDA of $20-25M, with 2027 targets of $715M revenue and $44M EBITDA, alongside a CEO transition to Natalia Noblet effective April 1, 2026.

• ·Cash and equivalents $66.3M, total debt $180.9M, net debt $114.7M as of Dec 31, 2025.
• ·Adjusted net debt $137.7M, TTM adjusted EBITDA $39.8M, leverage ratio 3.46x (covenant max 3.75x).
• ·Credit facility maturity extended to July 1, 2027.
• ·2030 targets: revenue $850M-$1B, EBITDA $80-120M (9.5%-12.0% margin).
• ·Q4 adjusted EBITDA $3.4M (1.7% of sales); FY adjusted EBITDA margin 2.9%.

12-03-2026

Gyre Therapeutics reported full-year 2025 revenue of $116.6 million, up 10.2% YoY from $105.8 million, driven by launches of Etorel® ($4.6M) and Contiva® ($5.5M), though ETUARY® grew only slightly to $106.1 million and generic revenue declined; Q4 revenue surged 33.3% YoY to $37.2 million, but income from operations fell to $11.5 million from $16.2 million amid 14.8% higher operating expenses, with net income dropping to $9.9 million. The company announced a $300 million all-stock acquisition of Cullgen, expected to close in Q2 2026, and provided 2026 revenue guidance of $100.5-111.0 million, implying a 4.8-13.8% YoY decline. Pipeline progress includes planned Hydronidone NDA submission in H1 2026 and completion of enrollment in 272-patient Phase 3 pirfenidone pneumoconiosis trial.

• ·Q4 2025 income from operations declined to $0.1M from $0.7M YoY.
• ·Q4 2025 net loss of $1.4M vs net income of $0.6M YoY.
• ·Full-year R&D expense up 14.2% to $13.7M.
• ·Final patient completion in Phase 3 pirfenidone PD trial expected Q3 2026.

12-03-2026

Kodiak Gas Services, Inc. announced via press release that its subsidiary, Kodiak Gas Services, LLC, priced a private offering of $1.0 billion aggregate principal amount of 5.875% senior unsecured notes due 2031. The announcement was filed under Item 8.01 Other Events, with the press release attached as Exhibit 99.1.

• ·Event date: March 11, 2026
• ·Filing date: March 12, 2026
• ·Notes are privately offered and not for sale in jurisdictions where unlawful

12-03-2026

Activate Energy Acquisition Corp., a blank check company, announced the resignation of director Andrew Childs on February 1, 2026, effective immediately and not due to any disagreement with the company. On March 4, 2026, the Board appointed Paul Moore, an oil/gas upstream expert with experience at Todd Corporation, Santos Limited, and Woodside Petroleum, and Keith Byer, a former Deloitte Senior Managing Director specializing in finance and risk, as new directors effective immediately. There are no arrangements, family relationships, or material interests involving the new directors.

• ·Company is an emerging growth company incorporated in Cayman Islands, listed on Nasdaq Global Market.
• ·Resignation of Andrew Childs unrelated to operations, policies, or practices.
• ·New directors have no family relationships with other directors/officers or material interests under Item 404(a).

12-03-2026

AllianceBernstein Holding L.P. filed an 8-K on March 12, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, furnishing a news release announcing preliminary assets under management (AUM) as of February 28, 2026. The AUM release is attached as Exhibit 99.01. No specific AUM figures, period-over-period comparisons, or performance metrics were disclosed in the filing body.

• ·Date of earliest event reported: March 11, 2026
• ·Registrant address: 501 Commerce Street, Nashville, TN 37203
• ·Trading symbol: AB (NYSE)

12-03-2026

Eagle Point Credit Company Inc. disclosed in an 8-K filing that management's unaudited estimate of the net asset value per share of its common stock as of February 28, 2026, ranged between $4.31 and $4.41. No prior period NAV or performance comparisons were provided in the filing.

• ·Filing date: March 12, 2026; Earliest event date: March 11, 2026
• ·Principal executive offices: 600 Steamboat Road, Suite 202, Greenwich, CT 06830
• ·Registrant is incorporated in Delaware; CIK: 0001604174; EIN: 47-2215998

12-03-2026

Eagle Point Income Company Inc. filed an 8-K disclosing management's unaudited estimate of the net asset value per share of its common stock as of February 28, 2026, ranging between $12.15 and $12.25. The filing lists the company's securities registered on the New York Stock Exchange, including common stock (EIC), 5.00% Series A Term Preferred Stock due 2026 (EICA), and 8.00% Series C Term Preferred Stock due 2029 (EICC). No comparative data or performance metrics were provided.

• ·Filing date: March 12, 2026; Date of earliest event reported: March 11, 2026

12-03-2026

IGC Pharma, Inc. entered into a Securities Purchase Agreement dated March 5, 2026, with Vanquish Funding Group Inc. for the issuance of a bridge note with an aggregate principal amount of $353,050 (including $46,050 OID), closing on or about March 6, 2026, with potential additional tranches up to $2,015,000 over the next 12 months. The note is convertible into common stock, posing potential dilution risk to existing shareholders given 92,868,241 shares outstanding out of 600,000,000 authorized. This unregistered securities offering relies on exemptions under the 1933 Act, providing short-term financing but at a costly OID.

• ·Agreement relies on SEC exemptions under the 1933 Act for unregistered sale.
• ·No material adverse changes since September 30, 2025, per company representations.
• ·Buyer is an accredited investor; securities may bear restrictive legends.

12-03-2026

Plum Acquisition Corp. IV, a Cayman Islands SPAC, entered into a Business Combination Agreement dated March 8, 2026, with Controlled Thermal Resources Holdings Inc. and its merger sub, outlining a domestication to Delaware followed by a merger where the target survives. Supporting Company Stockholders representing at least 60% of votes have committed to approve the transaction via Transaction Support Agreements. No financial terms such as valuation, share exchange ratios, or PIPE amounts are disclosed in the filing.

• ·Agreement executed March 8, 2026; SEC 8-K filed March 12, 2026.
• ·Domestication to occur at least two business days prior to Closing.
• ·Transaction includes Registration Rights Agreement and Lock-Up Agreement at Closing.
• ·Intended tax treatment as tax-free reorganizations under Section 368 of the Code.

12-03-2026

Solid Biosciences Inc. announced positive interim data from the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for Duchenne muscular dystrophy as of February 23, 2026 data cutoff, with 40 participants dosed and the therapy generally well-tolerated using a steroid-only regimen. Key results include robust microdystrophin expression (mean 60% by western blot at Day 90, 91% at Day 360), restored beta-sarcoglycan (60-69%) and nNOS activity (33-35%), plus biomarker reductions indicating improved muscle integrity (e.g., 38% CK, 43% ALT at Day 90). The company aligned with FDA on Phase 3 IMPACT DUCHENNE design, with first dosing anticipated in Q1 2026 and further updates mid-2026.

• ·Trial conducted at 15 sites across United States, Canada, Italy, and United Kingdom; dosing ongoing.
• ·FDA alignment on Phase 3 design announced February 9, 2026; participant screening underway; additional FDA meetings planned H1 2026.
• ·Updated corporate presentation made available on company website March 11, 2026.
• ·Baselines for western blot and mass spectrometry: 0% mean normal dystrophin.

12-03-2026

Hepion Pharmaceuticals, Inc. filed its 10-K annual report on March 12, 2026, emphasizing substantial risks including the need to raise additional capital to continue as a going concern and uncertainties in product development. Key milestones for Rencofilstat (formerly CRV431) include potential payments of $500K upon FDA approval of its first NDA, $1M on net sales exceeding $350M, and $3M exceeding $750M. No current financial performance data or period-over-period comparisons are detailed in the provided content.

• ·Risks include potential dilution from acquisitions, higher integration costs, and assumption of liabilities.

12-03-2026

Serve Robotics Inc. reported revenues of $2.7M for the year ended December 31, 2025, up 46% YoY from $1.8M, with Customer A sales rising to 37% of total revenues from 26% while Customer B fell to 18% from 65%. However, cost of revenues exploded 855% to $18.0M, driving gross loss to $15.4M from $0.1M, operating expenses surged 155% to $97.4M, and net loss widened 159% to $101.4M; cash used in operations increased to $80.2M while financing activities provided $261.2M, growing total assets to $368M and stockholders' equity to $351M.

• ·Customer C receivables 30% of total AR at Dec 31 2025 (N/A in 2024)
• ·Customer D receivables 18% of total AR at Dec 31 2025 (N/A in 2024)
• ·Net loss per common share - basic and diluted: $(1.63) in 2025 vs $(1.07) in 2024
• ·Research and development expenses up 87% YoY to $45.3M
• ·General and administrative expenses up 268% YoY to $37.1M
• ·Property and equipment, net $47.0M at Dec 31 2025 (up from $12.0M)
• ·Goodwill $15.5M and intangible assets $31.3M at Dec 31 2025 (both new)

12-03-2026

CION Investment Corp's total investments at fair value decreased 4.0% YoY to $1.81B as of December 31, 2025 from $1.89B, driven by a 12.3% decline in senior secured first lien debt to $1.37B (80.8% of portfolio) while equity investments grew 31.5% to $315M (18.5%). Investment income fell 4.6% to $241M and gross portfolio yield dropped to 9.15% from 10.96%, resulting in a net decrease in net assets of $21M versus a $34M increase in 2024, amid higher realized and unrealized losses. The number of portfolio companies reduced to 89 from 105, though average portfolio company EBITDA rose to $59.1M from $53.6M.

• ·Stock traded at average discount to NAV of ~30% in 2025 quarters, worsening from ~25% in 2024.
• ·Quarterly distributions stable at $0.36 per share in 2025 (up from mix of $0.34-$0.41 in 2024).
• ·Total estimated annual expenses 19.08% of average net assets, including 11.68% interest on borrowed funds.
• ·Net portfolio activity: net sales of $104M in 2025 vs $22M in 2024.

12-03-2026

For the year ended December 31, 2025, New ERA Energy & Digital, Inc. reported net revenues of $885,400, up 66.2% YoY from $532,780 in 2024, primarily driven by higher natural gas net sales. However, a massive $12.1M impairment expense led to total costs and expenses surging 91.4% to $25.4M, while interest expense ballooned 530% to $4.8M; as a result, the net loss more than doubled to $29.6M from $13.8M. General and administrative expenses remained essentially flat at -0.1% YoY.

• ·Natural gas gross sales $2.5M in 2025 (up from $1.3M in 2024); NGL revenues declined to $240K from $254K; Oil revenues dropped to $0 from $27K.
• ·Loss from operations worsened 92.4% to $24.5M from $12.7M.
• ·Total other income (expenses) deteriorated 1,052.1% to $5.1M loss from $0.4M loss, driven by higher interest expense and new losses on debt extinguishment ($577K) and JV investment ($119K).

12-03-2026

Braemar Hotels & Resorts Inc. reported portfolio-wide weighted average occupancy of 67.37%, ADR of $410.00, and RevPAR of $276.21 for the year ended December 31, 2025, with total hotel net income of -$13.0M and hotel EBITDA of $164.2M across 3,028 rooms. While properties like Pier House Resort & Spa achieved 3.2% YoY revenue growth to $30.8M and net margin expansion to 40.4%, and Bardessono Hotel saw 4.9% revenue increase, others declined including The Ritz-Carlton St. Thomas with 8.7% YoY revenue drop to $67.9M and 19% EBITDA decline, Park Hyatt Beaver Creek with 5.0% revenue decline, and Sofitel Chicago Magnificent Mile posting a sharp net income swing to -$28.7M from $1.2M. Overall performance was mixed with flat to declining revenues at several major properties and persistent net losses at multiple hotels.

• ·Four Seasons Resort Scottsdale Hotel EBITDA $28.0M; ADR $867.26; RevPAR $522.22
• ·The Ritz-Carlton Sarasota Hotel EBITDA $25.1M
• ·Cameo Beverly Hills Hotel EBITDA -$4.0M and net income -$8.4M
• ·Portfolio includes properties in AZ, FL, U.S. Virgin Islands, Puerto Rico, DC, CO, PA, IL, CA

12-03-2026

Immersion Corp's FY ended April 30, 2025 total revenues surged to $1.56B, primarily from the June 10, 2024 acquisition of Barnes & Noble Education contributing $1.48B in product and rental income, with consolidated net income of $93.6M versus $17.8M in the prior four-month stub period. Immersion's standalone royalty and license revenue grew to $74.1M, driven by fixed-fee licenses up over 1,000% to $62.5M year-over-year to CY2023, but per-unit royalties declined 59% to $11.6M. However, operating cash flow shifted to a use of $57.6M, quarterly revenues trended downward post-acquisition (e.g., $616M in Q ended Oct 2024 to $471M in Q ended Jan 2025), and interest expense emerged at $14.3M.

• ·Barnes & Noble Education acquired on June 10, 2024.
• ·Diluted EPS attributable to Immersion stockholders: $0.73 (Q ended Jan 31, 2025), $0.93 (Q ended Oct 31, 2024).
• ·Cash and equivalents: $72.6M as of Apr 30, 2025 (Immersion $63.6M, BNED $9.1M) vs $56.1M Dec 31, 2023.
• ·Goodwill from acquisition: $69.2M as of Apr 30, 2025.
• ·Impairment loss: $1.2M in FY25.

12-03-2026

Velocity Financial, Inc. reported robust growth in total loans UPB to $6.5B at December 31, 2025 (+28% YoY from $5.1B), net income of $105M (+53% YoY from $68M), and improved ROE of 17.5% (up from 14.4%), driven by 35% higher interest income and net interest margin expansion to 3.19%. However, provision for credit losses surged 395% YoY to $5.8M, nonperforming loans UPB rose slightly to $555M (though % improved to 8.5% from 10.7%), and average loan balances remained flat around $390k.

• ·Weighted average coupon increased to 9.74% at Dec 31, 2025 from 9.53% (2024) and 8.88% (2023).
• ·Net interest income grew 37% YoY to $186M in 2025.
• ·Pre-tax ROE improved to 24.4% in 2025 from 20.3%.

12-03-2026

Odyssey Health, Inc. reported a sharply widened net loss of $3.6M for the three months ended January 31, 2026 (vs. $0.22M YoY), and $4.1M for the six months (vs. $1.24M YoY), driven by $2.57M in financing costs, higher interest expense, and derivative liabilities changes, with no revenue generated. Cash improved significantly to $0.62M from $0.02M at July 31, 2025, supported by $1.17M in net proceeds from notes payable over six months. However, total liabilities rose to $11.3M from $7.0M, and stockholders' deficit deepened to $10.6M from $7.0M.

• ·Derivative liabilities: $3.94M at Jan 31, 2026 (none at Jul 31, 2025)
• ·Notes payable net: $2.17M at Jan 31, 2026 (vs. $1.88M at Jul 31, 2025)
• ·Net cash used in operating activities six months: $0.57M (vs. $0.30M prior year)
• ·Common stock issued for debt conversions: 3.14M shares during six months

12-03-2026

Deutsche Bank's 2025 total net revenues remained flat at €31.4B compared to €31.5B in 2024, with net interest income up 3% to €15.7B but noninterest income down 4% and trading gains (FVTPL) declining 19% to €4.6B. Profit attributable to shareholders rose 58% YoY to €5.8B, boosted by a 10% drop in noninterest expenses to €20.7B (driven by 21% lower general and administrative costs) and 7% reduced provisions for credit losses. The bank proposes a dividend of €1.00 ($1.17) per share for 2025, with a 33% payout ratio.

• ·Proposed dividend €1.00 ($1.17) per share for 2025 (up from €0.68 in 2024), 33% payout ratio on basic EPS.
• ·2024 net interest income declined 6% YoY from 2023.
• ·Equity Plan Rules and Restricted Share Plan Rules listed for 2021-2026 as exhibits.

12-03-2026

Sohu.com Ltd reported consolidated revenues declining slightly YoY from $601M in 2023 to $598M in 2024 (-0.4%) and further to $584M in 2025 (-2.4%), reflecting flat to modest contraction amid ongoing challenges in advertising and marketing services. However, net income attributable to Sohu swung from a $30M loss in 2023 and $100M loss in 2024 to a $394M profit in 2025, primarily driven by a $444M income tax benefit. Total assets decreased 6% YoY to $1.64B as of Dec 31, 2025 from $1.73B in 2024, with cash and equivalents down 20% to $128M while shareholders' equity rose to $1.28B.

• ·Net cash used in operating activities 2023: $26M
• ·Net cash used in investing activities 2023: $292M
• ·Net cash used in financing activities 2023: $7M
• ·Risks include potential impacts from Chinese regulations on VIE consolidation and revenue transfer
• ·Potential advertiser shift from brand advertising to sales-driven promotions

12-03-2026

News Corporation disclosed updates related to its $1B stock repurchase program via an 8-K filing, including information provided to the Australian Securities Exchange (ASX) attached as Exhibits 99.1 and 99.2 for daily transaction disclosures, if any. The program authorizes repurchases of up to $1B in aggregate of Class A (NWSA) and Class B (NWS) common stock. No specific repurchase transactions or volumes were detailed in the filing.

• ·Filing date: March 12, 2026; Earliest event date: March 11, 2026
• ·Securities: Class A Common Stock (NWSA, Nasdaq Global Select Market), Class B Common Stock (NWS, Nasdaq Global Select Market)

12-03-2026

KLA Corporation hosted an investor day on March 12, 2026, with presentations by President and CEO Richard Wallace, EVP and CFO Bren Higgins, and other executives; materials are available on the company's IR website. On March 11, 2026, the Board approved a quarterly dividend increase to $2.30 per share (21% rise from $1.90 declared in February 2026), effective starting with the May 2026 declaration. Additionally, the Board authorized a new $7B share repurchase program, supplementing the existing April 2025 program with $3.94B remaining as of December 31, 2025.

• ·Investor day webcast replay and presentation slides available at https://ir.kla.com
• ·Share repurchases to be conducted in compliance with SEC requirements and other legal standards, with flexibility in timing, method, and amount at company's discretion
• ·Future dividends and repurchases subject to Board's discretion, financial condition, and other factors

12-03-2026

Vivid Seats reported Q4 2025 Marketplace GOV of $580.6M, down 42% YoY from $994.4M, and revenues of $126.8M, down 37% YoY, with Adjusted EBITDA dropping sharply to $0.8M from $34.2M; full year 2025 saw GOV decline 31% to $2.7B and revenues fall 26% to $570.8M, alongside a net loss of $721.5M versus prior year profit, driven by $723M in impairment charges. FY2025 Marketplace orders decreased to 8,336 from 11,556 while Resale orders remained essentially flat at 428 versus 431. The company provided Q1 2026 guidance of $570-620M GOV and $8-10M Adjusted EBITDA, and reaffirmed FY2026 outlook of $2.2-2.6B GOV and $30-40M Adjusted EBITDA.

• ·Q4 2025 event cancellations negatively impacted Marketplace GOV by $13.5M vs $21.1M in Q4 2024; FY 2025 by $60.7M vs $95.9M.
• ·Goodwill decreased to $283.9M as of Dec 31, 2025 from $943.1M as of Dec 31, 2024.
• ·Q1 2026 guidance includes cash balance of $125-135M.
• ·Redeemable noncontrolling interests reduced to $0 from $352.9M year-over-year.

12-03-2026

Build-A-Bear Workshop reported record fiscal 2025 total revenues of $529.8 million, up 6.7% YoY, with net retail sales growing 5.6% and commercial/international franchising up 21.6%, though consolidated e-commerce demand declined 5.5% and was hit harder in Q4 at -13.6%. Pre-tax income was nearly flat at a record $67.2 million (vs. $67.1 million prior year) despite $11 million in tariff impacts, while Q4 pre-tax income fell 21.8% to $21.5 million from $27.5 million due to $6 million tariffs, higher medical/labor costs, and SG&A pressures; diluted EPS rose to a record $3.99 FY (+5%) from $3.80. The company returned $39.0 million to shareholders, increased its quarterly dividend 4.5% to $0.23 per share, and guided FY2026 revenue for mid-single-digit growth but pre-tax income for a mid-single-digit decline to low-single-digit growth amid ongoing tariffs.

• ·Q4 capex $12.7 million; FY2025 inventory up 17.8% YoY to $82.2 million due to tariffs and sales support needs.
• ·FY2026 guidance includes ~$16 million tariff costs (at 10% rate), $3 million longer-range investments, net new units >=50, commercial revenue growth >=20%, capex $22-25 million, D&A ~$16 million, tax rate ~24%.
• ·No borrowings under revolving credit facility at FY-end; $100 million repurchase program authorized Sept 11, 2024.

12-03-2026

Utz Brands, Inc. issued Definitive Additional Proxy Materials (DEFA14A) for its 2026 Annual Meeting of Stockholders on April 23, 2026, at 9:00 a.m. ET via live webcast. Key proposals include the election of four Class III Directors (Timothy Brown, Christina Choi, Roger Deromedi, Dylan Lissette) to serve until the 2029 Annual Meeting, a non-binding advisory vote to approve executive compensation, and ratification of Grant Thornton, LLP as independent auditors for the fiscal year ending January 3, 2027. The Board recommends voting 'FOR' all three proposals; proxy materials are available online at eqproxyportal.com/eq/utz.

• ·Paper or email copies of proxy materials must be requested by April 9, 2026.
• ·Virtual meeting registration at register.proxypush.com/utz using control number.
• ·Voting available 24/7 at www.proxypush.com/utz.

12-03-2026

Sleep Number Corp reported FY2025 net sales of $1,411.5M, down 16% YoY from $1,682.3M amid 17% declines in retail comparable-store sales and online/phone/chat sales, leading to an operating loss of $46.6M versus a $22.9M profit and a net loss of $132.0M compared to $20.3M prior year. While gross profit margins remained stable at 59.0%, operating expenses fell to $879.5M (down 10% excluding restructuring and non-recurring items, a $137.1M reduction), and average revenue per smart bed unit rose to $6,060 from $5,818. Adjusted EBITDA declined to $78.3M from $119.6M.

• ·Restructuring costs increased to $50.7M in FY2025 from $18.1M in FY2024.
• ·Cash used in operating activities swung to -$3.3M in FY2025 from +$27.1M in FY2024.
• ·Free cash flow was -$17.7M in FY2025 versus +$3.6M in FY2024.
• ·Inventory obsolescence write-off of $9.6M in FY2025.
• ·Weighted-average shares basic and diluted: 22.9M in FY2025.
• ·Net loss per share diluted: -$5.77 in FY2025 versus -$0.90 in FY2024.

12-03-2026

GPGI reported strong Q4 2025 results with Non-GAAP Net Sales up 17% YoY to $118M, GAAP Net Income of $43M (up 189% from prior loss), and Pro Forma Adj. EBITDA up 41% to $43M at 36.5% margin. Full year 2025 Non-GAAP Net Sales grew 10% to $462M with Pro Forma Adj. EBITDA up 24% to $171M, though GAAP Net Loss widened to $136M. The company completed its business combination with Husky Technologies, rebranded to GPGI, refinanced debt, initiated a quarterly dividend, and provided strong 2026 guidance for Pro Forma Adj. Net Sales of $2.183-2.228B and EBITDA of $620-650M.

• ·Q4 2025 Non-GAAP Gross Margin 55.7% (up 360 bps YoY)
• ·FY 2025 Non-GAAP Gross Margin 56.3% (up 420 bps YoY)
• ·Spin-off of Resolute Holdings on February 28, 2025, leading to equity method accounting
• ·Husky Technologies acquisition completed January 2026
• ·Earnings conference call on March 12, 2026 at 8:00 a.m. EDT
• ·2026 Outlook: Pro Forma Adj. Free Cash Flow $325-375M; Non-GAAP Year-end Net LTM Leverage <3.0x

12-03-2026

Ollie’s Bargain Outlet Holdings, Inc. reported strong Q4 FY2025 results with net sales up 16.8% YoY to $779.3M and comparable store sales +3.6%, while full-year net sales rose 16.6% to $2.65B with comps +3.7% and a record 86 new stores opened, bringing total to 645 stores. Net income increased 25% to $85.6M in Q4 ($1.39 diluted EPS) and 20% to $240.6M for the year ($3.89 EPS), supported by Ollie’s Army loyalty growth of 12.1% to 17M members; however, gross margin declined 80 bps to 39.9% due to price investments, and Adjusted EBITDA margin remained flat at 16.3% in Q4. The company provided FY2026 outlook for 75 new stores, net sales of $2.985-3.013B, and ~2% comp growth.

• ·SG&A expenses as % of net sales decreased 130 bps to 24.2% in Q4 FY2025.
• ·Pre-opening expenses decreased 53.3% to $2.3M in Q4 FY2025.
• ·FY2026 outlook includes capital expenditures of $103-113M and share repurchases of ~$100M.
• ·Total assets increased to $2.95B from $2.56B as of Jan 31, 2026.

12-03-2026

BK Technologies Corp reported FY2025 net sales of $86.1M, up 12% YoY from $76.6M, driven by strong US sales growth of 13% to $85.0M, though international sales declined 35% to $1.1M. Gross margin expanded significantly to 48.8% from 37.9%, boosting net income to $13.5M (+62% YoY) from $8.4M, while SG&A expenses rose 23% to $26.0M. Total assets grew to $63.8M from $51.5M, supported by cash surging to $22.8M, but risks from economic pressures on dealers/suppliers and stock price volatility were highlighted.

• ·Basic EPS $3.69 FY2025 vs $2.35 FY2024 (+57%)
• ·Diluted EPS $3.44 FY2025 vs $2.25 FY2024 (+53%)
• ·Operating income $16.0M FY2025 vs $7.8M FY2024 (+104%)
• ·Total stockholders’ equity $44.7M Dec 31 2025 vs $29.8M Dec 31 2024 (+50%)
• ·Common stock outstanding: 3,733,733 shares Dec 31 2025 vs 3,571,879 Dec 31 2024

12-03-2026

CareCloud, Inc. (CCLDO) filed an 8-K on March 12, 2026, reporting results of operations and financial condition (Item 2.02), departure or appointment of officers (Item 5.02), Regulation FD disclosure (Item 7.01), and exhibits including EX-99.1 (Item 9.01). The filing references unregistered securities sale and preliminary officer change events, but no specific financial metrics, performance comparisons, or detailed changes are provided in the available content excerpt. No positive or negative quantitative shifts identifiable due to lack of data.

• ·Filing items: 2.02 (Results of Operations), 5.02 (Officer Changes), 7.01 (Reg FD Disclosure), 9.01 (Exhibits including EX-99.1)
• ·Subcategory noted: Unregistered Securities Sale

12-03-2026

USA Rare Earth, Inc. filed an 8-K on 2026-03-12 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also covers Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). No specific details on the officer position affected, nature of the change (appointment or resignation), reasons, timing, or any quantitative financial metrics are disclosed.

• ·Data completeness: LOW (<50%). Critical missing information: Officer name, title (e.g., CEO/CFO), action (appointment/resignation/retirement), effective date, stated reason for change, board composition impact, details on Reg FD disclosure, other events, and exhibits listed.